Clinical Trials Logo

Carcinoma of the Head and Neck clinical trials

View clinical trials related to Carcinoma of the Head and Neck.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03733210 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods [positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations].

NCT ID: NCT02626000 Completed - Clinical trials for Carcinoma of the Head and Neck

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

MASTERKEY232
Start date: April 6, 2016
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

NCT ID: NCT00865098 Completed - Clinical trials for Carcinoma of the Head and Neck

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Start date: March 2009
Phase: Phase 2
Study type: Interventional

This study is conducted in Japanese newly diagnosed locally advanced SCCHN patients in order to assess tolerability and feasibility of Cetuximab plus concomitant boost radiotherapy (RT) regimen (the study treatment) and its safety profile (i.e. AEs: adverse events). In addition, efficacy (i.e. anti-tumor effect) of the study treatment is also evaluated.

NCT ID: NCT00050388 Completed - Clinical trials for Head and Neck Cancer

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.